Vitiligo in a patient receiving infliximab for refractory ulcerative colitis
Arab Journal of Gastroenterology. 2011; 12 (2): 109-111
in English
| IMEMR
| ID: emr-123886
ABSTRACT
Infliximab is a chimerical monoclonal antibody that inhibits pro-inflammatory activity of tumour-necrosis factor alpha [TNF alpha] and it is the primary biological agent used in the treatment of moderate-to-severe ulcerative colitis [UC]. We report a case of vitiligo following infliximab administration in a patient with refractory UC. The case serves as a reminder of adverse cutaneous reactions induced by TNF alpha -antagonist therapy
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Main subject:
Vitiligo
/
Colitis, Ulcerative
/
Tumor Necrosis Factor-alpha
Type of study:
Case report
Limits:
Humans
/
Male
Language:
English
Journal:
Arab J. Gastroenterol.
Year:
2011
Similar
MEDLINE
...
LILACS
LIS